Actelion Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline enter into exclusive collaboration to realize the full potential of almorexant in sleep disorders and beyond

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- ALLSCHWIL, SWITZERLAND - 27 June 2008 - Actelion Ltd (SWX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for bosentan (Tracleer®) to extend its use in Pulmonary Arterial Hypertension (PAH).

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- ALLSCHWIL, SWITZERLAND - 20 June 2008 - Actelion Ltd (SWX: ATLN) announced today that data published in The Lancet[1] show that, in mildly symptomatic pulmonary arterial hypertension (PAH) patients (WHO functional class II - WHO FC II), bosentan (Tracleer®) prevented clinical deterioration by significantly delaying time to clinical worsening and reduced the number of patients worsening to WHO FC III/IV. A significant reduction in pulmonary vascular resistance and a positive trend in increasing the 6MWD were also observed. The randomized, placebo-controlled EARLY (Endothelin Antagonist tRial in miLdlY symptomatic PAH patients) trial is the first and only trial conducted exclusively in a dedicated FC II PAH patient popul ...